Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gangl ET"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gosselin E; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Pop-Damkov P; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Xue A; Animal Sciences & Technology, Clinical Pharmacology and Safety Sciences, Biopharmaceutical R&D, AstraZeneca, Waltham, MA, USA., Markandu R; Early Oncology Clinical, Oncology R&D, AstraZeneca, Cambridge, UK., Mlynarski S; Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Finlay R; Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Schuller A; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca,Waltham, MA, USA., Ramsden D; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Gangl ET; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Waltham, USA.
Publikováno v:
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Aug 15; Vol. 246, pp. 116210. Date of Electronic Publication: 2024 May 08.
Autor:
Alonso-Gordoa T; Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: talonso@salud.madrid.org., Goodman M; Atrium Health Wake Forest Baptist, Winston-Salem, USA., Vulsteke C; Integrated Cancer Center, Maria Middelares General Hospital, Ghent; Center for Oncological Research, University of Antwerp, Antwerp, Belgium., Roubaud G; Institut Bergonié, Bordeaux, France., Zhang J; H. Lee Moffitt Cancer Center & Research Institute, Tampa., Parikh M; Hematology/Oncology Clinic, UC Davis Comprehensive Cancer Center, Sacramento, USA., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Azaro A; Oncology R&D, AstraZeneca, Cambridge., James GD; Medical Statistics Consultancy Ltd, London, UK., Cavazzina R; Oncology R&D, AstraZeneca, Cambridge., Gangl ET; BioPharma R&D, AstraZeneca, Boston., Thompson J; Oncology R&D, AstraZeneca, Cambridge., Pouliot G; Oncology R&D, AstraZeneca, Waltham., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg., Sweeney C; Dana-Farber Cancer Institute, Boston, USA.
Publikováno v:
ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103446. Date of Electronic Publication: 2024 Jun 04.
Autor:
Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Gerald.Falchook@sarahcannon.com., Reeves J; Florida Cancer Specialists South, Sarah Cannon Research Institute, Fort Meyers, FL, USA., Gandhi S; Florida Cancer Specialists South, Sarah Cannon Research Institute, St. Petersberg, FL, USA., Spigel DR; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Arrowsmith E; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., George DJ; Duke Cancer Institute, Durham, NC, USA., Karlix J; Sarah Cannon Research Institute, Gainesville, FL, USA., Pouliot G; Oncology R&D, AstraZeneca, Waltham, MA, USA., Hattersley MM; Oncology R&D, AstraZeneca, Waltham, MA, USA., Gangl ET; BioPharma R&D, AstraZeneca, Boston, MA, USA., James GD; Medical Statistics Consultancy Ltd, London, UK., Thompson J; Oncology R&D, AstraZeneca, Waltham, MA, USA., Russell DL; Oncology R&D, AstraZeneca, Waltham, MA, USA., Patel B; Oncology R&D, AstraZeneca, Cambridge, UK., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Lim E; Medical Oncology & Hematology-LHCP, Corewell Health Medical Group, Grand Rapids, MI, USA.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 72. Date of Electronic Publication: 2024 Mar 02.
Autor:
Lawson M; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cureton N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Ros S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cheraghchi-Bashi A; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Urosevic J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., D'Arcy S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Delpuech O; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fisher DI; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Lewis H; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Trueman D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Wali N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Williamson SC; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Montaudon E; Institut Curie, Paris, France., Derrien H; Institut Curie, Paris, France., Marangoni E; Institut Curie, Paris, France., Miragaia RJ; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gagrica S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Morentin-Gutierrez P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss TA; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Maglennon G; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Sutton D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Polanski R; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Rosen A; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cairns J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Zhang P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Critchlow SE; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Scott JS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Lindemann JPO; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Barry ST; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Morrow CJ; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Carnevalli LS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Cancer research [Cancer Res] 2023 Dec 01; Vol. 83 (23), pp. 3989-4004.
Autor:
Doshi AS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hernandez M; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Srinivasan S; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tentarelli S; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Griffin M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wang Y; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pop-Damkov P; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Prickett LB; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Kankkonen C; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden., Shen M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Martin MS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wu S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Castaldi MP; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts., Ghadially H; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Varnes J; Global Portfolio and Project Management, Waltham, Massachusetts., Gales S; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Henry D; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Hoover C; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Mele DA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Simpson I; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Mlynarski SN; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Finlay MRV; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Shao W; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645.
Autor:
Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Stead D; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Breed J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Carbajo RJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Chiarparin E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Cureton N; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Davey PRJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Fisher DI; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Gangl ET; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Grebe T; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Greenwood RD; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Hande S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Hatoum-Mokdad H; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Hughes SJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Hunt TA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Johnson T; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Kavanagh SL; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 OAA, United Kingdom., Klinowska TCM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Larner CJB; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 OAA, United Kingdom., Lawson M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Lister AS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Longmire D; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Marden S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States., McGuire TM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., McMillan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., McMurray L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Morrow CJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Nissink JWM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Moss TA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., O'Donovan DH; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Polanski R; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Stokes S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Thakur K; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Trueman D; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Truman C; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Tucker MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Wang H; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Whalley N; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States., Wu Y; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Yang B; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Yang W; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Feb 23; Vol. 66 (4), pp. 2918-2945. Date of Electronic Publication: 2023 Feb 01.